Table 1 Difference in patient characteristics between the TPF and PF groups in the observational and propensity-matched datasets
Characteristic | Observational dataset [cases (%)] | Propensity score-matched dataset [cases (%)] | ||||
|---|---|---|---|---|---|---|
TPF | PF | P | TPF | PF | P | |
Total | 315 (25.1) | 941 (74.9) | Â | 294 (50.0) | 294 (50.0) | Â |
Number of DSS events | 31 (9.8) | 228 (24.2) | Â | 28 (9.5) | 55 (18.7) | Â |
Gender | Â | Â | 0.649 | Â | Â | 0.114 |
 Male | 235 (74.6) | 715 (76.0) |  | 224 (76.2) | 206 (70.1) |  |
 Female | 80 (25.4) | 226 (24.0) |  | 70 (23.8) | 88 (29.9) |  |
Age | Â | Â | 0.147 | Â | Â | 0.740 |
 ≤ 45 | 172 (54.6) | 558 (59.3) |  | 162 (55.1) | 167 (56.8) |  |
 > 45 | 143 (45.4) | 383 (40.7) |  | 132 (44.9) | 127 (43.2) |  |
Histology | Â | Â | 0.376 | Â | Â | 0.362 |
 I | 0 (0) | 3 (0.3) |  | 0 (0) | 2 (0.7) |  |
 II | 18 (5.7) | 41 (4.4) |  | 18 (6.1) | 17 (5.8) |  |
 III | 297 (94.3) | 897 (95.3) |  | 276 (93.9) | 275 (93.5) |  |
T stage | Â | Â | 0.192 | Â | Â | 0.485 |
 T1 | 13 (4.1) | 22 (2.3) |  | 9 (3.1) | 4 (1.4) |  |
 T2 | 36 (11.4) | 126 (13.4) |  | 32 (10.9) | 28 (9.5) |  |
 T3 | 157 (49.9) | 436 (46.3) |  | 153 (52.0) | 162 (55.1) |  |
 T4 | 109 (34.6) | 357 (38.0) |  | 100 (34.0) | 100 (34.0) |  |
N stage | Â | Â | 0.364 | Â | Â | 0.377 |
 N0 | 25 (7.9) | 103 (10.9) |  | 25 (8.5) | 33 (11.2) |  |
 N1 | 93 (29.5) | 276 (29.3) |  | 85 (28.9) | 89 (30.3) |  |
 N2 | 141 (44.8) | 420 (44.7) |  | 133 (45.2) | 134 (44.6) |  |
 N3 | 56 (17.8) | 142 (15.1) |  | 51 (17.4) | 38 (12.9) |  |
Clinical stage | Â | Â | 0.649 | Â | Â | 0.456 |
 III | 165 (52.4) | 478 (50.8) |  | 157 (53.4) | 167 (56.9) |  |
 IV | 150 (47.6) | 463 (49.2) |  | 137 (46.6) | 127 (43.1) |  |
KPS | Â | Â | 0.837 | Â | Â | 0.176 |
 70–80 | 7 (2.2) | 25 (2.7) |  | 7 (2.4) | 2 (0.7) |  |
 ≥ 90 | 308 (97.8) | 916 (97.3) |  | 287 (97.6) | 292 (99.3) |  |
Smoking | Â | Â | 0.086 | Â | Â | 0.144 |
 Yes | 119 (37.8) | 409 (43.5) |  | 115 (39.1) | 97 (33.0) |  |
 No | 196 (62.2) | 532 (56.5) |  | 179 (60.9) | 197 (67.0) |  |
BMI | Â | Â | 0.638 | Â | Â | 0.602 |
 < 19 | 33 (10.5) | 96 (10.2) |  | 31 (10.6) | 29 (9.9) |  |
 19–24 | 200 (63.5) | 574 (61.0) |  | 185 (62.9) | 176 (59.8) |  |
 > 24 | 82 (26.0) | 271 (28.8) |  | 78 (26.5) | 89 (30.3) |  |
CDDP dose (mg/m2) | Â | Â | 0.741 | Â | Â | 0.438 |
 < 200 | 188 (59.7) | 551 (58.6) |  | 185 (62.9) | 195 (66.3) |  |
 ≥ 200 | 127 (40.3) | 390 (41.4) |  | 109 (37.1) | 99 (33.7) |  |
Number of IC cycles | Â | Â | 0.169 | Â | Â | 0.729 |
 < 2 | 54 (17.1) | 131 (13.9) |  | 46 (15.7) | 42 (14.3) |  |
 ≥ 2 | 261 (82.9) | 810 (86.1) |  | 248 (84.3) | 252 (85.7) |  |
Radiation technique |  |  | < 0.001 |  |  | 1.0 |
 IMRT | 263 (83.5) | 262 (27.9) |  | 242 (82.3) | 242 (82.3) |  |
 2D-CRT | 52 (16.5) | 679 (72.1) |  | 52 (17.7) | 52 (17.7) |  |